MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Wearable Devices in Movement Disorder Trials to Provide Objective Measures

C. Martino, A. Lledó, J. Hamlet, S. Mendick (Wilmington, USA)

Meeting: MDS Virtual Congress 2021

Abstract Number: 1294

Keywords: Bradykinesia, Parkinson’s

Category: Technology

Objective: To understand the validity of wearable devices in capturing objective motor and nonmotor symptoms of Parkinson’s Disease (PD) in addition to what has been captured by the rating scales in a clinical trial.

Background: Clinician Reported Outcomes (ClinRO) and patient reported outcomes (PRO) are standardly used in PD trials to assess the primary objective of the trial. However, PRO’s such as subject diaries are often completed outside of the prescribed timelines. Thus, there is value in obtaining continuous objective data in a real-time manner to support primary study objectives through capture of motor and non-motor symptoms, beyond the duration of a clinical visit.

Method: 110 subjects enrolled into an idiopathic PD study were given a wearable device that would assess bradykinesia, tremor, general activity, and sleep at baseline, Visit 5 and Visit 6. Subjects were verbally instructed how to use the device and were sent home to wear the device for 7 days prior to each of the 3 visits. The devices were returned to the office at the next scheduled study visit, at which time the site downloaded the data to the vendor’s database. There was no real-time reporting to capture whether subjects wore the device for a minimum of 70% of the day, at least 4 of the 7 assigned days, which would result in a valid recording.

Results: Usage data was received for 324 study visits, which is 98% of the expected data. The received data includes subjects who early terminated as well as those who wore the device more than three weeks. The device was to be worn for 7 days, and as assessed at least 4 days of recording will provide reliable measures. Overall 5% of subject visit data were deemed not valid because the subject didn’t wear the watch at least 4 out of 7 days.

Conclusion: The use of wearable devices to provide objective insights into daily activities is a valid tool to assess PD motor and non-motor symptoms. The value of the data received correlates with how closely the wearer follows the guidance in the protocol. When using a wearable or digital device, alerts should be implemented to remind the subject to use the device, and to alert site staff or the study team when the device isn’t being used as instructed. Written instruction and ‘live’ visibility are critical as events are occurring to improve reliability of the data. Ranges for “valid data” should be established prospectively.

To cite this abstract in AMA style:

C. Martino, A. Lledó, J. Hamlet, S. Mendick. Wearable Devices in Movement Disorder Trials to Provide Objective Measures [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/wearable-devices-in-movement-disorder-trials-to-provide-objective-measures/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to MDS Virtual Congress 2021

MDS Abstracts - https://www.mdsabstracts.org/abstract/wearable-devices-in-movement-disorder-trials-to-provide-objective-measures/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley